However, drugs targeting IL-6 and the IL-6 receptor, as well as downstream components of the IL-6 pathway, although not FDA approved for the treatment of HNSCC, have been FDA approved for other indications [27–29]. This evidence concerns the gene IL6 and head and neck squamous cell carcinoma.